A Phase 3 interventional study of IV Acetaminophen and IV Placebo 100 mL solution in Postoperative Pain and Hysterectomy, sponsored by Mallinckrodt. Completed at 27 sites in United States. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2016-10-21.
Sponsored by Mallinckrodt · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 118 studies testing acetaminophen in Pain, Postoperative — 11 open to participants now, 13 under way, 1 of them phase 3. Acetaminophen · Pain, Postoperative.
Among the 118 studies testing acetaminophen in Pain, Postoperative, this one is the 11th largest by enrollment, is one of 4 that started in 2006, is one of 20 in phase 3, and was the 3rd registered.
5,671 studies on the registry are indexed under Pain, Postoperative; 1,241 are open to participants now.
Browse Pain, Postoperative studies →11 of the 118 studies testing acetaminophen in Pain, Postoperative are open now, in 4 countries. Recruiting first, the newest first:
Northwestern University · Sites in United States
Ages 18–80
University of Puerto Rico · Sites in Puerto Rico
Ages 21–65
Seoul National University Hospital · Sites in Korea, Republic of
Ages 19+ · Women only · Healthy volunteers
McGill University Health Centre/Research Institute of the McGill University Health Centre · Sites in Canada
Ages 18+
Rothman Institute Orthopaedics · Sites in United States
Ages 18+
By country, each count listing its studies:
Acetaminophen: first FDA approval 1968 (NEOPAP). What it is approved for, and how studies give it, is on its page →
Of the 677 Pain, Postoperative studies recruiting now, 240 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.
This study: 18 Years to 75 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
118 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 12 · Phase 3 23 · Phase 4 53
First in 2002; this study’s year is marked. 4 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 331 is above the median of 75 across 4,850 interventional studies indexed under Pain, Postoperative.
Median enrollment 90 across the 118 interventional studies. Of the 88 that completed or were terminated, 41 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 118 have an industry lead sponsor. The 10 most frequent:
This study is registered under Mallinckrodt, one of the names counted as Keenova Therapeutics plc. Under that name alone:
Mallinckrodt is the lead sponsor of 87 studies on the registry; none are open to participants now.
Of its 15 completed or terminated interventional studies of FDA-regulated products, 15 (100%) have results posted.
10 studies in Pain, Postoperative by Keenova Therapeutics plc: none open now, none under way, none of them phase 3. Of 9 finished, 7 (78%) have results posted.
Among the 10 studies in Pain, Postoperative by Keenova Therapeutics plc, this one is the 2nd largest by enrollment, is the only one that started in 2006, is one of 8 in phase 3, and was the 1st registered.
Keenova Therapeutics plc’s Pain, Postoperative studies by the year they started, since 2003.
6 of the studies testing acetaminophen in Pain, Postoperative that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07571252University of Puerto RicoImpact of Preemptive Analgesia on Postoperative Pain in Orthognathic Surgery | 2026-12 |
| NCT06997016Baylor Research InstituteEnhanced Recovery After Surgery (ERAS) in Live Donor Kidney Transplant Recipients | 2027-06 |
| NCT03105518Brigham and Women's HospitalPredictors of Postoperative Pain Following Oocyte Retrieval for Assisted Reproduction | 2027-06-30 |
| NCT06613178McGill University Health Centre/Research Institute of the McGill University Health CentreIntravenous Acetaminophen After Cardiac Surgery - Definitive Study | 2027-07-01 |
| NCT07720791Konya City HospitalAcetaminophen vs Placebo for Postoperative Analgesia After Abdominal Surgery | 2027-07-15 |
Add all 6 to your calendar (.ics) → With an account.
Among the 118 studies testing acetaminophen in Pain, Postoperative, from their registry updates:
Among Keenova Therapeutics plc’s 10 in Pain, Postoperative:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will be investigating the efficacy and safety administration of multiple doses of intravenous (IV) acetaminophen (IVAPAP) in the 48 hour period following Gynecologic Surgery.
The research hypothesis is that IV Acetaminophen will provide greater reduction in pain intensity and greater pain relief for moderate and severe pain as compared to placebo in the 48 hours following surgery.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: IV Acetaminophen
Drug: IV Placebo 100 mL solution
Intravenous acetaminophen 1 g/100 mL
Also known as: IV Acetaminophen (IV APAP)
IV Placebo 100 mL solution dosed at same frequency as IV Acetaminophen every 6 hours (q6h)
Also known as: IV Placebo (non-active product)
Sum of Pain Intensity at Rest-Baseline to 24 Hours (SPI24rest), 1 Gram IV Acetaminophen vs. Placebo.
The Sum of Pain Intensity (SPI) score incorporates the analgesic effects on pain intensity (PI) from Baseline to 24 hours. SPI was measured by the 100 millimeter (mm) long Visual Analog Scale (VAS) over 24 hours after treatment. Subjects were asked to mark the level of pain they were experiencing at a certain timepoint on the scale The 100mm VAS scale was used with the left terminus (0 mm) of the scale "No Pain" and the right terminus (100 mm) with "Worst Pain Imaginable". The range of measurement is 0-2400 mm for 24 hours.
Time frame: Baseline (just prior to the first dose) through 24 hours
Sum Pain Intensity at Rest-Baseline to 48 Hours (SPI48rest), 1 Gram IV Acetaminophen vs. Placebo
The Sum of Pain Intensity (SPI) score incorporates the analgesic effects on pain intensity (PI) from Baseline to 48 hours. SPI was measured by the 100 millimeter (mm) long Visual Analog Scale (VAS) over 48 hours after treatment. Subjects were asked to mark the level of pain they were experiencing at a certain timepoint on the scale The 100 mm VAS scale was used with the left terminus (0 mm) of the scale "No Pain" and the right terminus (100 mm) with "Worst Pain Imaginable". The range of measurement is 0-4800 mm for 48 hours.
Time frame: Baseline (just prior to the first dose) through 48 hours
Subjects Who Experienced at Least One Treatment-emergent Adverse Event (TEAE)
Number of subjects who experienced at least one treatment emergent adverse event (TEAE) A TEAE is an adverse event that occurs on or after administration of the first dose of study medication (T0)
Time frame: First dose through 7 day follow up
Subjects Who Experienced at Least One Treatment-emergent Serious Adverse Event.
Number of subjects who reported SAEs during the study. A serious Adverse event (SAE) is defined as any untoward medical occurence at any dose of study medication that: Results in Death, Is Life Threatening, Requires inpatient hospitalization or causes prolongation of existing hospitalization, Results in persistent or significant disability/incapacity, Is a congenital anomaly/birth defect, or Is an important medical event
Time frame: 32 days following first dose of study medication.
Gynecologists and/or anesthesiologists were selected to participate as Principal Investigators.
| Milestone | IV Acetaminophen 1 g/100 mL Solution | IV Placebo 100 mL Solution |
|---|---|---|
| Started | 166 | 165 |
| Completed | 154 | 156 |
| Not completed | 12 | 9 |
| Withdrew: Adverse event | 1 | 2 |
| Withdrew: Withdrawal by subject | 7 | 3 |
| Withdrew: Protocol non-compliance | 2 | 2 |
| Withdrew: Lost to follow-up | 2 | 2 |
The Sum of Pain Intensity (SPI) score incorporates the analgesic effects on pain intensity (PI) from Baseline to 24 hours. SPI was measured by the 100 millimeter (mm) long Visual Analog Scale (VAS) over 24 hours after treatment. Subjects were asked to mark the level of pain they were experiencing at a certain timepoint on the scale The 100mm VAS scale was used with the left terminus (0 mm) of the scale "No Pain" and the right terminus (100 mm) with "Worst Pain Imaginable". The range of measurement is 0-2400 mm for 24 hours.
| units on a scale (in millimeters) | IV Acetaminophen 1 g/100 ml Solution | IV Placebo 100 ml Solution |
|---|---|---|
| Sum of Pain Intensity at Rest-Baseline to 24 Hours (SPI24rest), 1 Gram IV Acetaminophen vs. Placebo. | 1793.3 ± 481.49 | 1845.3 ± 420.21 |
Number of subjects who experienced at least one treatment emergent adverse event (TEAE) A TEAE is an adverse event that occurs on or after administration of the first dose of study medication (T0)
| Subjects | IV Acetaminophen 1g/100 ml Solution | IV Placebo 100 ml Solution |
|---|---|---|
| Subjects Who Experienced at Least One Treatment-emergent Adverse Event (TEAE) | 141 | 149 |
The Sum of Pain Intensity (SPI) score incorporates the analgesic effects on pain intensity (PI) from Baseline to 48 hours. SPI was measured by the 100 millimeter (mm) long Visual Analog Scale (VAS) over 48 hours after treatment. Subjects were asked to mark the level of pain they were experiencing at a certain timepoint on the scale The 100 mm VAS scale was used with the left terminus (0 mm) of the scale "No Pain" and the right terminus (100 mm) with "Worst Pain Imaginable". The range of measurement is 0-4800 mm for 48 hours.
| units on a scale (in millimeters) | IV Acetaminophen 1 g/100 ml Solution | IV Placebo 100 ml Solution |
|---|---|---|
| Sum Pain Intensity at Rest-Baseline to 48 Hours (SPI48rest), 1 Gram IV Acetaminophen vs. Placebo | 3612.4 ± 966.66 | 3718.2 ± 829.21 |
Number of subjects who reported SAEs during the study. A serious Adverse event (SAE) is defined as any untoward medical occurence at any dose of study medication that: Results in Death, Is Life Threatening, Requires inpatient hospitalization or causes prolongation of existing hospitalization, Results in persistent or significant disability/incapacity, Is a congenital anomaly/birth defect, or Is an important medical event
| Subjects | IV Acetaminophen 1 g/100 ml Solution | IV Placebo 100 ml Solution |
|---|---|---|
| Subjects Who Experienced at Least One Treatment-emergent Serious Adverse Event. | 11 | 14 |
Collected over Adverse Events were reported from the start of study medication until the follow up visit on Day 7 (+/- 2 days). Serious Adverse Events were collected for 32 days following start of study medication. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| IV Acetaminophen 1g/100 mL Solution | — | 11/166 (6.6%) | 135/166 (81.3%) |
| IV Placebo 100 mL Solution | — | 14/165 (8.5%) | 145/165 (87.9%) |
| Event | IV Acetaminophen 1g/100 mL Solution | IV Placebo 100 mL Solution |
|---|---|---|
| Accidental overdoseInjury, poisoning and procedural complications | 1/166 | 5/165 |
| IleusGastrointestinal disorders | 1/166 | 2/165 |
| Pelvic abscessInfections and infestations | 0/166 | 2/165 |
| SeromaInjury, poisoning and procedural complications | 2/166 | 0/165 |
| PyrexiaGeneral disorders | 1/166 | 1/165 |
| Abdominal abscessInfections and infestations | 0/166 | 1/165 |
| Vaginal infectionInfections and infestations | 0/166 | 1/165 |
| Postoperative ileusInjury, poisoning and procedural complications | 0/166 | 1/165 |
| AtelectasisRespiratory, thoracic and mediastinal disorders | 0/166 | 1/165 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 1/166 | 1/165 |
| Event | IV Acetaminophen 1g/100 mL Solution | IV Placebo 100 mL Solution |
|---|---|---|
| NauseaGastrointestinal disorders | 96/166 | 88/165 |
| ConstipationGastrointestinal disorders | 48/166 | 49/165 |
| PyrexiaGeneral disorders | 19/166 | 37/165 |
| VomitingGastrointestinal disorders | 37/166 | 28/165 |
| FlatulenceGastrointestinal disorders | 21/166 | 28/165 |
| PruritisSkin and subcutaneous tissue disorders | 24/166 | 21/165 |
| HeadacheNervous system disorders | 22/166 | 17/165 |
| InsomniaPsychiatric disorders | 18/166 | 10/165 |
| DizzinessNervous system disorders | 10/166 | 16/165 |
| TachycardiaCardiac disorders | 8/166 | 13/165 |
| Age, Categorical(Participants) | IV Acetaminophen 1 g/100 mL Solution | IV Placebo 100 mL Solution | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 163 | 161 | 324 |
| >=65 years | 3 | 4 | 7 |
| Sex: Female, Male(Participants) | IV Acetaminophen 1 g/100 mL Solution | IV Placebo 100 mL Solution | Total |
|---|---|---|---|
| Female | 166 | 165 | 331 |
| Male | 0 | 0 | 0 |
| Region of Enrollment(participants) | IV Acetaminophen 1 g/100 mL Solution | IV Placebo 100 mL Solution | Total |
|---|---|---|---|
| United States | 166 | 165 | 331 |
The record gives a start of Nov 2006, a primary completion of Sep 2007 and a completion of Sep 2007. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2010, 3 years 3 months after primary completion. A results delay was requested in Apr 2009.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Acetaminophen